September 29, 2014 News by Patricia Silva, PhD MS Patients Can Tolerate Exercise According to University of Vermont Study A new study conducted at theĀ Department of Rehabilitation and Movement Science of the University of Vermont, reinforces the idea that multiple sclerosis patients can handleĀ exerciseĀ regimens, despite their mobility difficulties, in order toĀ improve not only their motor capacities, but also their quality of life. Although over 90% of…
September 29, 2014 News by Patricia Silva, PhD Kessler Study Recommends Wellness Program for Multiple Sclerosis In today’s healthcare environment, it is often not enough that patients are provided with the latest treatments. Good health is not merely the absence of injury or disease, but overall wellness that includes mental, spiritual and social health. A group of investigators from the Kessler Foundation…
September 26, 2014 News by Patricia Silva, PhD Continuing Multiple Sclerosis Education To Be Offered at AIMS Live Meetings With multiple sclerosis (MS) prevalence rates still at concerning levels of 90 for every 100,000 Americans, researchers are continuously seeking to learn more about the disease, and are aggressively working to develop novel treatments and interventions for symptom management. This poses an ongoing challenge for healthcare professionals and academics,…
September 25, 2014 News by Patricia Silva, PhD Evotec Multiple Sclerosis Drug Studies Receive ā¬5 Million in New Funding Funding for continued research and development into understanding, treating, and eventually curing Multiple Sclerosis continues to accelerate. Evotec AG, aĀ German company that specializes in providing drug discovery resources to pharmaceutical and biotech companies, and learning institutions, has just announced the launch of its line-up of groundbreaking studies intoĀ MSĀ — an…
September 24, 2014 News by Patricia Silva, PhD Multiple Sclerosis Summit in Quebec to Feature “Deepelling” As Encouragement for Active MS Lifestyles Deepelling International conferences on multiple sclerosis (MS) typically gather the most accomplished experts and leading biotech companies under one roof to exchange discoveries and celebrate new hope for MS patients all over the world. Quebec is one of North America’s epicenters for MS research and developments. This year, on…
September 23, 2014 News by Patricia Silva, PhD Researchers Reveal Relevance of Microparticle Levels in MS, Clinically Isolated Syndrome Researchers are continuing to make headway in discovering new insights into how MS works, which in turn could lead to next-generation therapies. A new study shows that in the early stages ofĀ multiple sclerosisĀ (MS), plasma micro particles act as biomarkers as well as pathological factors that induce endothelial permeability and…
September 22, 2014 News by Patricia Silva, PhD Women with Disabilities Like Multiple Sclerosis Photographed for The Raw Beauty Project NYC Joy Nabors – The Raw Beauty Project NYC model living with Multiple Sclerosis In a bold movement aimed towards empowering disabled women to stand against social stigmas, the Christopher & Dana Reeve Foundation partnered with innovative visual arts project, Raw Beauty Project NYC, to showcase a series of photographs…
September 19, 2014 News by Patricia Silva, PhD Accelerated Cure Project for MS, EMD Serono To Study Treatment Outcomes The nonprofit organization Accelerated Cure Project for Multiple Sclerosis is going to sponsor the launch of theĀ Optimizing Treatment – Understanding Progression (OPT-UP) study in collaboration with biopharmaceutical companyĀ EMD Serono, Inc, a subsidiary of the german Merck KGaA. The study will enroll 2,500 MS…
September 19, 2014 News by Patricia Silva, PhD MuckFest MS Los Angeles 5K Mud Fun Run on October 25 MuckFestĀ® MS runners getting down and dirty for a cause. One of the more engaging ways to campaign for awareness and fundraising for a disease is hosting a sporting event. Be it a marathon, weight lifting, biking, or even ziplining, adding an element of fun in supporting a serious…
September 16, 2014 News by Patricia Silva, PhD Fatigue Felt by MS Patients May Be From Underdiagnosed Sleep Disorders The underlying cause ofĀ fatigue experienced by multiple sclerosis (MS) patients may be undiagnosed sleep disorders, according to a study conducted at the Department of Neurology of the University of California. Not only is that a problem in itself, but also an undiagnosed and untreated sleeping disorder may exacerbate the…
September 16, 2014 News by Patricia Silva, PhD Biogen’s Two-Year Study Confirms Plegridy’s Efficacy and Safety as Relapsing MS Treatment Biogen Idec revealed data from itsĀ second year of the phase 3 ADVANCE clinical trial for the study of Plegridy as a treatment for patients with relapsing forms of multiple sclerosis, which demonstrated the positive effects of the subcutaneous injectable therapyĀ beyond the first year…
September 16, 2014 News by Patricia Silva, PhD Merck Serono Awards ā¬1 Million at the Second Annual Grant for Multiple Sclerosis Innovation Biopharmaceutical companyĀ Merck Serono, a division of Merck, recently awardedĀ a total of ā¬1 million to the five winners of theĀ second annual Grant for Multiple Sclerosis Innovation (GMSI) at MS Boston 2014, the joint meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee…
September 15, 2014 News by Patricia Silva, PhD Teva, Active Biotech Present Positive Findings for RRMS Experimental Therapy Laquinimod During the 30th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) last week in Boston, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), together with Active Biotech (NASDAQ OMX NORDIC:ACTI), presented new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS)…
September 15, 2014 News by Patricia Silva, PhD Biogen Idec’s Study Reviews Positive Results Over Five Years of Tecfidera RRMS Treatment Biogen Idec presented theĀ five-year results from its ENDORSE phase 3 extension study of TecfideraĀ (dimethyl fumarate), which revealed that the treatment is able to provide strong and sustained efficacy to patients with relapsing-remitting multiple sclerosis (RRMS), at last week’sĀ ACTRIMS-ECTRIMSĀ summit. Not only did…
September 12, 2014 News by Patricia Silva, PhD Novartis Presents Impressive Gilenya Updates at MSBoston 2014 This past Wednesday, September 10th, the largest, most anticipated multiple sclerosis (MS) convention — the 6th Joint ACTRIMS-ECTRIMS Triennial Meeting, MSBoston 2014 — kicked off with a whopping 8,000 registered attendees, all eager to learn more about the latest developments in MS. One of the highlights of the event…
September 12, 2014 News by Patricia Silva, PhD EMD Serono’s Multiple Sclerosis Pipeline On Display at 2014 ACTRIMS-ECTRIMS Meeting in Boston During the joint meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee for Treatment and Research in MS (ECTRIMS), taking place in Boston from September 10-13, EMD Serono, Inc., a subsidiary of Merck KGaA, will present new data from its multiple sclerosis…
September 11, 2014 News by Patricia Silva, PhD Receptos to Present Data on RMS Treatment Trial at MSBoston 2014 Biopharmaceutical companyĀ Receptos, Inc. announced that they will review data from the phase 2 portion of theĀ RADIANCE trial,Ā the company’s phase 2 / 3 study testing RPC1063 in the treatment ofĀ Relapsing Multiple Sclerosis (RMS).Ā The data is being presented at theĀ largest meeting dedicated to multiple sclerosis…
September 11, 2014 News by Patricia Silva, PhD Multiple Sclerosis Trial for Lisinopril Granted $1.4 Million in New Funding From NCATS Transparency Life Sciences, LLCĀ (TLS), the first clinical-stage drugĀ development company based on open innovation in the world, recentlyĀ receivedĀ a $1.4 millionĀ Small Business Innovation Research (SBIR) grant intended for its phase IIa proof-of-concept study, which is assessing the utility of the ACE inhibitor lisinopril as an adjunctive treatment for patients with multiple…
September 11, 2014 News by Patricia Silva, PhD MS Diagnosis Inspires Miss Kentucky For 2015 Miss America Pageant For a 23 year-old country girl from the University of Kentucky to go through the harsh demands of an American beauty pageant, there has to be an inspiration stemming from something more profound than a desire for world peace, a sash, and a shiny crown. Last month, on July 12th,…
September 10, 2014 News by Patricia Silva, PhD Largest Multiple Sclerosis Conference Begins in Boston; 8,000 Attendees Expected See below for the complete schedule for this year’sĀ ACTRIMS-ECTRIMS Multiple Sclerosis conference in Boston, and stay tuned to Multiple Sclerosis News throughout the week for continuing coverage on breaking science and research news for MS. For the past few weeks, Multiple Sclerosis News Today has been following the lead-up…
September 9, 2014 News by Patricia Silva, PhD Genzyme’s Aubagio, Lemtrada MS Therapies To Showcase at Conference During the 30th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) taking place in Boston between September 10th and 13th, Genzyme, a Sanofi company, will present its multiple sclerosis (MS) pipeline with a new group of trial treatments for early development of MS.
September 9, 2014 News by Patricia Silva, PhD Large Multiple Sclerosis Product Update To Be Presented By Biogen Biogen Idec, one of the first true biotech companies specializing in products indicated forĀ neurodegenerative diseases, hematologic conditions, and autoimmune disorders, is preparing to present over 90 poster presentations during this week’s 6th Joint ACTRIMS-ECTRIMS Meeting. The event is scheduled to take place from Wednesday, September 10th through Saturday the…
September 8, 2014 News by Patricia Silva, PhD Novartis to Present New Gilenya Data at ACTRIMS-ECTRIMS Meeting Those attending this week’sĀ ACTRIMS-ECTRIMSĀ conventionĀ set to take place on the 10th of September until the 13th in Boston, can expect Swiss pharmaceutical companyĀ NovartisĀ to present promising findings on Gilenya (fingolimod)Ā — the company’s leading oral formulation for relapsing-remitting multiple sclerosis (RRMS). In previously completed studies and clinical trials,…
September 5, 2014 News by Patricia Silva, PhD Future MS Therapies Could Target, Treat Intestinal Barrier A new study, entitled, āIntestinal barrier dysfunction develops at the onset of experimental autoimmune encephalomyelitis, and can be induced by adoptive transfer of auto-reactive T cellsā conducted at University of Lund, Sweden, published on PlosOneĀ by the research group of Dr. Shahram Lavasani in collaboration with…
September 4, 2014 News by Patricia Silva, PhD Walking Speed in MS Patients May Indicate Worsening of Disease A dynamic research team composed of doctors and scientists recently completed and published a study that sought to gain a better understanding of walking impairment, as it is manifested in patients living with multiple sclerosis (MS), a neurodegenerative disease wherein the impulse-conducting myelin sheath is attacked by the body’s own…
September 4, 2014 News by Patricia Silva, PhD Autoimmune Diseases Like MS Can Be “Switched Off,” According To Bristol Scientists Researchers from the University of Bristol have found a way of convert the function of cells into protecting the body instead of destroying healthy tissue, in what could be an important breakthrough for the treatment of debilitating autoimmune diseases in which the immune system mistakenly attacks the body, like…
September 3, 2014 News by Patricia Silva, PhD Importance of Brain Shrinkage for MS Treatment Measure Focus of Novartis Presentation Novartis has announced that it will present new analyses and redefinedĀ treatment goals for multiple sclerosis (MS) at theĀ 2014 Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis Meeting (ACTRIMS-ECTRIMS), which is taking place in Boston, between September 10 and 13. Novartis claims to have…
September 3, 2014 News by Patricia Silva, PhD Researchers Advance New Stem Cell Methods for Remyelination in MS Patients In-vitro laboratory experiments using stem cells have long-since been the subject of debate between scientists and naturalists, but when it comes to developing effective methods to grow human cells and tissue for use in a potentially life-saving procedure or restoration of bodily function, researchers are increasingly more confident that…
September 2, 2014 News by Patricia Silva, PhD Mylan’s Generic Copaxone Injection ANDA Approved for Filling by the FDA The U.S. Food and Drug Administration (FDA) acceptedĀ theĀ abbreviated new drug application (ANDA)Ā forĀ filingĀ of aĀ Glatiramer Acetate InjectionĀ for the treatment of patients with relapsing forms of multiple sclerosis (MS).
September 2, 2014 News by Patricia Silva, PhD Yoga Can Improve MS Patients’ Quality of Life According to Rutgers’ Researchers YogaĀ improves the quality of life of patients who suffer from multiple sclerosis, as recently concluded during a study of its benefits in increasing mental health, concentration, bladder control, walking, balance, motor coordination and vision, as well as in decreasing pain and fatigue. Researchers fromĀ Rutgers’ School of Health Related Professions…